Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma

NCT02023905 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT02023905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02023905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Terminated
Start date
March 19, 2014
Completion date
September 30, 2021
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

low grade glioma, mixed oligoastrocytomas, oligodendrogliomas, world health organization (who) grade ii astrocytomas